DrugBank

MAY 15, 2024

In fact, it's one of the most exciting areas in drug research today. With billions in funding and innovative research, we're starting to see strategies that can tackle these tough targets. One approach is to look beyond the traditional drug molecule.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Agency IQ

NOVEMBER 27, 2023

BY KIRSTEN MESSMER, PHD, RAC | NOV 17, 2023 4:46 PM CST Quick background on nitrosamines in global medicinal products Nitrosamines are a large and diverse class of chemicals, with more than 300 different structurally distinct species known today. This was eventually expanded to include biological products as well.

Regulations 40

Regulations Production FDA Packaging 40

Agency IQ

AUGUST 11, 2023

BY KARI OAKES AUG 7, 2023 10:20 PM CDT Quick background on nitrosamines in pharmaceutical products Nitrosamines are a large and diverse class of chemicals, with more than 300 different structurally distinct species known today. In 2018, NDMA was first detected in the active pharmaceutical ingredient (API) for valsartan, a blood pressure drug.

FDA 40

FDA Science Production Regulations 40

Drug Target Review

FEBRUARY 11, 2025

Drugs that were developed and commercialised 30+ years ago were relatively simple small molecules. Todays small molecules are far larger, more complex, and chase highly specific (and difficult to hit) targets, thereby increasing the chances of undesired side effects.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59